secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2025-06-17T23:59:59+00:00
Accession:  0001193125-25-141739
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA Breakthrough Therapy Designation for DYNE-101 in DM1; revised Accelerated Approval path
--------------------------------------------------------------------------------

- FDA granted Breakthrough Therapy Designation to DYNE-101 for myotonic dystrophy type 1 (DM1).
- Revised ACHIEVE trial protocol submitted with vHOT as primary endpoint (60 patients, 3:1 randomization).
- Enrollment in Registrational Expansion Cohort expected to complete Q4 2025; data mid-2026, submission late 2026.
- New 12-month data: sustained vHOT improvement of 3.3 sec at 6 months; QMT strength improved 10% at 6 mo, 20% at 12 mo.
- Cash $677.5M as of March 31, 2025; runway extended into Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000119312525141739/0001193125-25-141739-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000119312525141739/d47489d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-141739

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer